Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline findings from the final analysis of the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy (cisplatin and either 5-fluorouracil or capecitabine) for the first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Gilead Sciences’ selonsertib has failed to achieve primary end point in the Phase 3 study of nonalcoholic steatohepatitis (NASH).
Teva Pharmaceutical Industries said that it will stop an ongoing clinical development program of its humanized monoclonal antibody fremanezumab in cluster headaches due to futility.
Eli Lilly and Company (Lilly) has announced that its psoriatic arthritis drug Taltz (ixekizumab) succeeded in a phase 3 trial in patients with non-radiographic axial spondyloarthritis (nr-axSpA).
Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced that the first patient has been dosed in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumor-specific anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC).
Pfizer and Eli Lilly’s phase 3 study has showed mixed results of painkiller tanezumab in the treatment of patients with osteoarthritis (OA).
Alnylam Pharmaceuticals has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1).
Gilead Sciences, Inc. and Novo Nordisk A/S today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH).
Janssen Pharmaceutical said that a phase 3 trial evaluating SYMTUZA (darunavir 800mg, cobicistat 150mg, emtricitabine 200mg and tenofovir alafenamide 10mg D/C/F/TAF) showed that a high percentage of HIV patients recorded an undetectable viral load through 48 weeks after rapid initiation of the drug.
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.